Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.

ABSTRACT:

Background

Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate. Thus, rapid recovery and continuous maintenance of platelet count during chemotherapy cycles are crucial in patients with CIT. Thrombopoietin (TPO) and its receptor, myeloid proliferative leukemia (MPL) protein, play a major role in platelet production. Although several MPL agonists have been developed to regulate thrombopoiesis, none have been approved for the management of CIT due to concerns regarding efficacy or safety. Therefore, the development of effective MPL agonists for treating CIT needs to be further expanded.

Methods

Anti-MPL ant

SUBMITTER: Shin J 

PROVIDER: S-EPMC10230746 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature